Related Experiment Video
Updated: Jan 9, 2026
09:25
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
19.6K
Management of pediatric bone sarcomas.
Leighton Elliott1, David M Loeb2, Matteo Trucco3
1Department of Medicine and Pediatrics, University of Florida College of Medicine, UF Health Cancer Center, Gainesville, FL.
Current Opinion in Pediatrics
|December 9, 2025
Summary
Outcomes for children with metastatic or relapsed bone sarcomas have stagnated. New strategies combining tyrosine kinase inhibitors with chemotherapy and improved risk stratification show promise for better pediatric cancer treatment.
Area of Science:
- Pediatric Oncology
- Skeletal System Neoplasms
- Cancer Therapeutics
Background:
- Localized pediatric bone sarcomas (osteosarcoma and Ewing sarcoma) are often curable, but outcomes for metastatic or relapsed cases remain poor.
- Current frontline therapies for osteosarcoma and Ewing sarcoma have not significantly advanced in decades.
- Emerging technologies like circulating tumor DNA (ctDNA) offer potential for improved diagnosis and risk stratification.
Purpose of the Study:
- To synthesize recent clinically relevant developments in the diagnosis, risk stratification, local control, systemic therapy, and survivorship of pediatric bone sarcomas.
- To review advancements informing treatment strategies for osteosarcoma and Ewing sarcoma in children and adolescents.
- To highlight challenges and future directions in managing pediatric bone cancers.
Main Methods:
- Literature review of recent clinical developments and ongoing research in pediatric bone sarcoma.
- Synthesis of data on diagnostic tools, therapeutic approaches, and survivorship care.
- Analysis of emerging technologies and clinical trial outcomes.
Main Results:
- Standard frontline therapies for osteosarcoma and Ewing sarcoma remain unchanged.
- Circulating tumor DNA (ctDNA) shows promise for validating and incorporating into treatment regimens.
- Tyrosine kinase inhibitor-chemotherapy combinations are a current strategy to improve upfront therapy, with novel drug combinations being tested.
- Debate continues regarding optimal surgical approaches for pulmonary metastasectomy in osteosarcoma.
Conclusions:
- While single-agent checkpoint inhibitors have shown limited efficacy, rational tyrosine kinase inhibitor-chemotherapy combinations, improved biologic risk stratification (ctDNA, MYC, STAG2), and standardized local control are reshaping care.
- Near-term priorities include biomarker-anchored upfront trials and supportive care to reduce late effects.
- Clinical trials are crucial for accessing potentially paradigm-shifting therapeutic strategies for pediatric bone tumors.
Related Concept Videos
01:27Fractures: Bone Repair
4.9K
Treatment for a fracture is based on the type of break, the bone affected, and the patient's age.
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the...
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the...
4.9K
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
01:29Bone Disorders
5.0K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.0K
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
176
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
176
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
195
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
195